Earnings summaries and quarterly performance for CytomX Therapeutics.
Executive leadership at CytomX Therapeutics.
Board of directors at CytomX Therapeutics.
Research analysts who have asked questions during CytomX Therapeutics earnings calls.
Mitchell Kapoor
H.C. Wainwright & Co.
5 questions for CTMX
Also covers: HALO, INM, IONS +7 more
PL
Peter Lawson
Barclays PLC
4 questions for CTMX
Also covers: ADAP, ARVN, BPMC +15 more
AR
Anupam Rama
JPMorgan Chase & Co.
3 questions for CTMX
Also covers: APLS, BBIO, BOLD +18 more
ET
Edward Tenthoff
Piper Sandler Companies
2 questions for CTMX
Also covers: ARVN, ARWR, CAPR +16 more
Matthew Biegler
Oppenheimer & Co. Inc.
2 questions for CTMX
Also covers: ALLO, ARVN, FULC +2 more
Nabeel Nissar
Jefferies
2 questions for CTMX
D(
Dan (on for Mitchell Kapoor)
H.C. Wainright
1 question for CTMX
ED
Etzer Darout
BMO Capital Markets
1 question for CTMX
Also covers: ARVN, EXEL, GMAB +7 more
J
Jeff
B. Riley
1 question for CTMX
Also covers: NIO
JS
Jiale Song
Jefferies Financial Group Inc.
1 question for CTMX
Also covers: ACRS, CRVS, CVAC +12 more
Joe Catanzaro
Piper Sandler
1 question for CTMX
Also covers: AADI, CNTB, IMAB +1 more
JC
Joseph Catanzaro
Wolfe Research, LLC
1 question for CTMX
Also covers: AADI, CPRX, CRDF +8 more
Liang Cheng
Jefferies
1 question for CTMX
Also covers: AADI, INO, VXRT
RD
Robert Driscoll
Wedbush Securities
1 question for CTMX
Also covers: CMPX
Recent press releases and 8-K filings for CTMX.
CytomX Therapeutics Discusses Varseta-M Clinical Progress and Future Plans
CTMX
New Projects/Investments
Guidance Update
- CytomX's lead clinical program, Varseta-M, a masked EpCAM ADC, demonstrated promising initial Phase I data in metastatic colorectal cancer (CRC) with a 28% objective response rate and 94% disease control in a difficult-to-treat patient population.
- The company expanded enrollment for Varseta-M to approximately 100 patients across three active doses, with a Q1 data update planned to inform optimal dosing for later phase development.
- CytomX aims to discuss a potential registrational study for Varseta-M with the FDA by mid-year, with a goal to start the study no later than the first half of 2027.
- A combination study with bevacizumab for Varseta-M is planned for Q1, and an initial clinical update for their other Phase I asset, 801, is expected in the second half of this year.
Feb 11, 2026, 9:30 PM
CytomX Therapeutics Outlines Strategy for Masked EpCAM ADC CX-2051
CTMX
New Projects/Investments
- CytomX Therapeutics is focused on its lead clinical program, CX-2051, a masked EpCAM ADC, which leverages the company's masked biologics technology to target EpCAM, a broad solid tumor antigen, while aiming to mitigate systemic toxicities that limited prior EpCAM therapies.
- Initial Phase 1 data for CX-2051 in last-line metastatic colorectal cancer (CRC) patients demonstrated a 28% objective response rate and 94% disease control (17 out of 18 patients), with an early progression-free survival estimate of 5.8 months.
- The company expanded enrollment for CX-2051 across three active doses (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg) to a target of approximately 100 patients for a data update in Q1.
- CytomX aims to discuss a potential registrational study with the FDA by mid-year, with a goal to start no later than the first half of 2027, initially targeting a late-line CRC study.
- The company also has another Phase 1 asset, 801 (interferon alpha-2b), for PD-1 refractory melanoma, with an initial clinical update expected in the second half of this year.
Feb 11, 2026, 9:30 PM
CytomX Therapeutics Provides Update on Lead Clinical Programs CX-2051 and CX-801
CTMX
New Projects/Investments
Guidance Update
- CytomX's lead clinical program, CX-2051, a masked EpCAM ADC, targets solid tumors, with an initial focus on colorectal cancer (CRC).
- Early Phase 1 data for CX-2051 in last-line metastatic CRC demonstrated a 28% objective response rate and 94% disease control, with an early estimate of 5.8 months progression-free survival.
- The company expanded enrollment for CX-2051 to approximately 100 patients for a Q1 2026 data update, aiming to inform dose selection and potential registrational study discussions by mid-year, with a goal to start a registrational study no later than the first half of 2027.
- The other Phase 1 asset, CX-801, an interferon alpha-2b program, is in dose escalation for late-line melanoma, with an initial clinical update expected in the second half of 2026.
Feb 11, 2026, 9:30 PM
CytomX Provides Clinical Development Update for Vaseta M and CX801 at J.P. Morgan Healthcare Conference
CTMX
New Projects/Investments
Guidance Update
- CytomX is expanding its Phase 1 study for Vaseta M, an EpCAM-targeting Topo-1 ADC for colorectal cancer, to over 100 patients and anticipates a data update by the end of Q1 2026.
- Initial Vaseta M data from May 2025 demonstrated a 28% confirmed overall response rate (ORR) and 5.8 months of preliminary progression-free survival (PFS) in late-line metastatic CRC, targeting a US market opportunity of over $5 billion in the third-line setting alone.
- The company is also progressing CX801, a Probody version of interferon alpha-2b for melanoma, with the goal of achieving proof of concept by the end of 2026 in combination with Keytruda, with initial combination data expected by year-end.
- CytomX maintains a robust cash position, providing funding well into Q2 2027, excluding potential milestones or new business development.
Jan 14, 2026, 5:00 PM
CytomX Provides Clinical Program Updates and Financial Outlook at J.P. Morgan Healthcare Conference
CTMX
New Projects/Investments
Guidance Update
- CytomX, an oncology-focused biotech company, is advancing two clinical programs: Vaseta M (EpCAM-targeting ADC for colorectal cancer) and CX801 (Probody interferon alpha-2b for melanoma).
- For Vaseta M, the Phase 1 study is expanding to over 100 patients, with a data update expected by the end of Q1 2026. Previous data from May 2025 showed a 28% confirmed overall response rate in late-line colorectal cancer.
- The company aims to achieve proof of concept for CX801 in combination with Keytruda by the end of 2026, with initial combination data anticipated by that time.
- CytomX reports a robust cash position, providing funding well into Q2 2027, excluding potential milestones or new business development.
Jan 14, 2026, 5:00 PM
CytomX Provides Updates on Vaseta M and CX801 Clinical Programs
CTMX
New Projects/Investments
Guidance Update
- CytomX is expanding its Phase 1 study for Vaseta M, an EpCAM-targeting Topo-1 ADC for colorectal cancer, to more than 100 patients and anticipates a data update by the end of Q1 2026.
- The company previously reported a 28% confirmed overall response rate and 5.8 months of preliminary progression-free survival for Vaseta M in late-line colorectal cancer patients.
- CytomX aims to achieve proof of concept for CX801, a Probody version of interferon alpha-2b for melanoma, in combination with Keytruda by the end of 2026.
- The company maintains a robust cash position, providing a financial runway well into Q2 2027, excluding potential milestones or new business development.
Jan 14, 2026, 5:00 PM
CytomX Provides Updates on PROBODY® Platform and Clinical Programs
CTMX
New Projects/Investments
Guidance Update
- CytomX is advancing its PROBODY® Platform with key clinical programs, Varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.
- Varseta-M (EpCAM PROBODY® Topo-1 ADC) demonstrated encouraging interim Phase 1 clinical data in late-line metastatic CRC (data cutoff April 7, 2025), showing a 28% confirmed overall response rate (ORR) and 94% disease control. Phase 1 expansion data is expected in Q1 2026.
- The company anticipates releasing Phase 1 data for CX-801 in combination with KEYTRUDA® for advanced melanoma by 2026 Year-End.
- CytomX has a cash runway extending to Q2 2027, excluding any potential milestones or new business development, and maintains partnerships with Bristol Myers Squibb, Amgen, Astellas, Regeneron, and Moderna.
Jan 14, 2026, 5:00 PM
CytomX Highlights Positive Clinical Data for CX-2051 and CX-801, Reports Strong Financial Position
CTMX
Guidance Update
New Projects/Investments
- CytomX reported encouraging Phase 1 data for CX-2051 in metastatic colorectal cancer, demonstrating a 28% confirmed response rate and 5.8 months progression-free survival in late-stage patients. The company aims for a registrational path as monotherapy, with an update expected in Q1 2026 and a bevacizumab combination study initiating in Q1 2026.
- Early Phase 1 data for CX-801 in melanoma showed the drug's mechanism is working as designed, activating interferon-responsive genes and recruiting T cells. A combination study with Keytruda is ongoing, with data anticipated in late 2026.
- The company is in a robust financial position, with $144 million in cash at the end of Q3 (subsequently $150-$158 million with ATM), providing funding into Q2 2027. This enables continued clinical development for both CX-2051 and CX-801.
- The positive clinical data for CX-2051 has validated CytomX's Probody platform, and the company remains open to additional platform partnerships.
Dec 4, 2025, 6:00 PM
CytomX Discusses Clinical Pipeline and Financial Outlook at Piper Sandler Conference
CTMX
Product Launch
New Projects/Investments
Guidance Update
- CytomX reported encouraging Phase 1 data for its masked anti-EpCAM ADC, CX-2051, in metastatic colorectal cancer, showing a 28% confirmed response rate and 5.8 months progression-free survival in late-line patients. The company plans to provide an update in Q1 next year and aims for a registrational path as monotherapy, with a combination study with bevacizumab initiating in Q1 next year.
- Early Phase 1 data for CX-801, a masked interferon alpha-2b, in melanoma demonstrated compelling biomarker data, including activation of interferon responsive genes and recruitment of CD8 positive T cells into the tumor microenvironment. A combination study with Keytruda began earlier this year, with data expected in late 2026.
- CytomX ended Q3 with $144 million in cash, providing funding into Q2 2027, which supports ongoing clinical studies for CX-2051 and CX-801.
- The company is open for additional platform partnerships on the discovery side, leveraging its Probody platform.
Dec 4, 2025, 6:00 PM
CytomX Provides Updates on Clinical Pipeline and Financial Outlook
CTMX
New Projects/Investments
Guidance Update
- CytomX reported encouraging Phase 1 data for CX-2051 (EpCAM ADC) in metastatic colorectal cancer in May 2025, demonstrating a 28% confirmed response rate and 5.8 months progression-free survival in late-stage patients. An update on the expanded Phase 1 study is anticipated in Q1 2026.
- Early Phase 1 data for CX-801 (masked interferon alpha-2b) in melanoma, presented at SITC, showed activation of interferon responsive genes and recruitment of CD8 positive T cells into the tumor microenvironment. Combination therapy with Keytruda began in 2025, with data expected in late 2026.
- The company concluded Q3 2025 with $144 million in cash, which is expected to fund operations into Q2 2027.
Dec 4, 2025, 6:00 PM
Quarterly earnings call transcripts for CytomX Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more